Literature DB >> 20376142

Cancer: drug-tolerant insurgents.

Paul Workman, Jon Travers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20376142     DOI： 10.1038/464844a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  11 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Binding of pRB to the PHD protein RBP2 promotes cellular differentiation.

Authors:  Elizaveta V Benevolenskaya; Heather L Murray; Philip Branton; Richard A Young; William G Kaelin
Journal:  Mol Cell       Date:  2005-06-10       Impact factor: 17.970

Review 3.  Microbial phenotypic heterogeneity and antibiotic tolerance.

Authors:  Neeraj Dhar; John D McKinney
Journal:  Curr Opin Microbiol       Date:  2007-01-09       Impact factor: 7.934

4.  Where lies the blame for resistance--tumor or host?

Authors:  Charles L Sawyers
Journal:  Nat Med       Date:  2007-10       Impact factor: 53.440

Review 5.  Resistance mechanisms to cancer chemotherapy.

Authors:  Kelly Marie Redmond; Timothy Richard Wilson; Patrick Gerard Johnston; Daniel Broderick Longley
Journal:  Front Biosci       Date:  2008-05-01

Review 6.  Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance.

Authors:  S Cara; I F Tannock
Journal:  Ann Oncol       Date:  2001-01       Impact factor: 32.976

7.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

8.  The clonal evolution of tumor cell populations.

Authors:  P C Nowell
Journal:  Science       Date:  1976-10-01       Impact factor: 47.728

9.  Darwin and evolutionary tales in leukemia. The Ham-Wasserman Lecture.

Authors:  Mel Greaves
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

Review 10.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962
View more
  5 in total

Review 1.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.

Authors:  Weiwen Fan; Zhe Tang; Lihong Yin; Bei Morrison; Said Hafez-Khayyata; Pingfu Fu; Honglian Huang; Rakesh Bagai; Shan Jiang; Adam Kresak; Scott Howell; Amit Vasanji; Chris A Flask; Balazs Halmos; Henry Koon; Patrick C Ma
Journal:  Cancer Res       Date:  2011-05-09       Impact factor: 12.701

3.  Cancer quasispecies and stem-like adaptive aneuploidy.

Authors:  Domenico Napoletani; Michele Signore; Daniele C Struppa
Journal:  F1000Res       Date:  2013-12-06

Review 4.  Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments.

Authors:  Antti P Jekunen
Journal:  J Oncol       Date:  2015-01-29       Impact factor: 4.375

5.  Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.

Authors:  Praveena S Thiagarajan; Xiaoliang Wu; Wei Zhang; Ivy Shi; Rakesh Bagai; Patrick Leahy; Yan Feng; Martina Veigl; Daniel Lindner; David Danielpour; Lihong Yin; Rafael Rosell; Trever G Bivona; Zhenfeng Zhang; Patrick C Ma
Journal:  Oncotarget       Date:  2016-12-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.